Disruptive Pharma AB is engaged in the development and commercialization of Improved and Safe drug products based on Pharma-MMC, our patented drug delivery technology. Pharma-MMC enables amorphous API stabilization, solubility enhancement and for unique drug formulations. As CEO, my focus will be on leadership, business development and identifying strategic business partnerships within our field. Development of selected Pharma-MMC enhanced drug products will translate into a bright future for Disruptive Pharma. The establishment of the Disruptive Pharma company has enabled us to focus on our business model, development of proprietary and commercial drugs based on the Pharma-MMC platform.

Disruptive Materials - Pharma - develops drug products based on Pharma-MMC, a pharmaceutical grade mesoporous magnesium carbonate material. Pharma-MMC is a proprietary drug delivery technology for amorphous stabilization and solubility enhancement of drug substances and for unique drug formulations - addressing unmet industry need. My focus is strategic leadership of Disruptive Materials - Pharma and commercialization of novel drug products enabled by the Pharma-MMC drug delivery platform, including drug delivery applications, and to seek business partnerships within our field.

Disruptive Materials Pharma unit develops pharmaceutical grade mesoporous magnesium carbonate material (Pharma-MMC) within drug delivery applications. The properties of Pharma-MMC allow drugs to be loaded to achieve a controlled release or solubility improvement. My focus is mainly on commercialization of the world-record breaking Pharma-MMC drug delivery platform, including drug products and drug delivery, and to seek business partnerships within our field.

Olink Bioscience is focused on developing and commercializing enabling molecular tools for life science research and molecular diagnostics. Our primary goal is to develop high-end products and/or tools meeting unmet clinical and research needs with a significant market potential.Our pipeline contains exciting projects targeting unmet industry needs. We are committed to continue the Olink tradition of innovation and delivering high-end products for the biosciences community.

Cadila Pharmaceuticals is one of the largest pharmaceutical companies in India with an impressive track record within clinical development and bringing innovative products to the market. Our product basket includes branded and generic formulations covering more than 45 therapeutic segments, active pharmaceutical ingredient (API) and intermediates. I am responsible for Cadila’s interface with local stakeholders in European countries, to establish business relationships between companies and other organizations, and Cadila Pharmaceuticals. Within this role I am responsible for investments in drug development and drug discovery as well as evaluating potential acquisitions. Established a unique business model for commercial interactions with small biotech companies.

Aegate’s core principle is Patient Safety: To protect patients from falsified, recalled or expired medicines. We operate a highly secure real-time system that verifies the authenticity of medicines instantly. This operates seamlessly from manufacturer to pharmacy, and fully meets the requirements of European legislation and fully complies with the Falsified Medicines Directive (FMD).I am responsible for Aegate’s interface with local stakeholders in the Nordic countries, to establish suitable relationships between companies and other organizations, and Aegate in the Region.

Our goal is to develop novel treatments for neurodegenerative disorders based on the Company's proprietary technology. I am responsible for all commercial aspects, pharmaceutical development, intellectual property rights and business development. I was one of those who took the initiative to found BioChromix Pharma AB in 2009. It was purely a strategic decision to separate BioChromix diagnostics from BioChromix Pharma's drug discovery. Focus: a unique class of compounds for the treatment of diseases involving protein misfolding in neurodegenerative diseases, such as Alzheimer’s disease (AD) and Amyotrophic Lateral Sclerosis (ALS). Advanced the company’s CNS project from Lead Optimization stage to the pre-clinical phase. Additional responsibilities: HR and intellectual properties.All assets were divested to an Austrian company during 2014. Their goal is to continue the clinical development through the earlier phases and to establish a partnership with a big pharma to finalize the development.

Novel treatments for neurodegenerative disorders based on the Company's proprietary technology.

BioChromix is an exciting company developing breakthrough Imaging, Diagnostics and R&D tools for Alzheimer’s disease (AD). Our products will help scientist to better understand the disease and aid pharmaceutical companies to validate/test new treatments. My main responsibilities as the chief executive officer are to lead and facilitate the development and commercialization of our unique products. Another important for me task has been to maintain and develop BioChromix patent portfolio. During this work I have obtained substantial experience in strategic business development, critical technical assessment and intellectual property rights.

Research, instrument development and supervising PhD-students.

Applied Biochemistry @ Biomolecular and Organic Electronics

Co-founder and the first chairman of the board. Additional responsibilities included business development, head of R&D and intellectual property rights.